Efficacy and Safety of an Active Pulsed Electromagnetic Field for the Treatment of Osteoarthritis of the Knee

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-31

Study Completion Date

2019-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The hypothesis of this study is that exposure to PEMF alters the cytokine environment of OA joints associated with a reduction of inflammation and improved homeostasis of the extracellular matrix (ECM), both potentially effecting symptomatic relief of OA pain, reducing cartilage breakdown, stimulate new cartilage formation therefore preserving joint structure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pilot Study of PEMF Therapy in Treatment of Post-operative Pain Following Total Knee Arthroplasty

NCT02211534

Post-Operative Pain Following Total Knee Arthroplasty

COMPLETED NA

The Effect of PEMF for Patients With Knee OA

NCT05548712

Knee Osteoarthritis Knee Pain Chronic

RECRUITING NA

"Bimodal vs Unimodal High-Intensity Pulsed Electromagnetic Field Therapy in Older Adults With Knee Osteoarthritis"

NCT07198750

Knee Osteoarthritis Osteoarthritis Osteo Arthritis of the Knee +1 more

RECRUITING NA

Magnetic Field Therapy Versus Transcutaneous Electrical Nerve-stimulation in Knee Osteoarthritis

NCT06406231

Knee Osteoarthritis

RECRUITING NA

To Investigate the Effect of PEMF for Knee OA Patients

NCT05442697

Knee Osteoarthritis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The hypothesis of this study is that exposure to PEMF alters the cytokine environment of OA joints associated with a reduction of inflammation and improved homeostasis of the extracellular matrix (ECM), both potentially effecting symptomatic relief of OA pain, reducing cartilage breakdown, stimulate new cartilage formation therefore preserving joint structure. The primary objective of this study is to prospectively determine, at 12 months post treatment, the safety and efficacy of treating OA of the knee with PEMF. Safety will be assessed through adverse event collection. Study subjects will be randomized in a 2:1 ratio (active: placebo control) to either an active or placebo control (inactive) Physio-Stim device. The study is powered to detect a significant difference between groups when 120 subjects (80 active: 40 placebo control) have completed the study. Planned enrollment for the study is 150 subjects, to allow for an attrition rate of 20%.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis, Knee

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active PEMF

Subjects have a 2 out of 3 chance to get the active device which emits a Pulsed Electromagnetic Field (PEMF) from the Physio-Stim Model 3315OA device. Double blind randomization

Group Type ACTIVE_COMPARATOR

Orthofix Physio-Stim Model 3315OA

Intervention Type DEVICE

Active device emits PEMF signal; placebo/control device does not emit PEMF signal

Control/no PEMF

Subjects have a 1 out of 3 chance of getting the control/placebo device which does not emit Pulsed Electromagnetic Field (PEMF) from the Physio-Stim Model 3315A device. Double blind randomization

Group Type PLACEBO_COMPARATOR

Orthofix Physio-Stim Model 3315OA

Intervention Type DEVICE

Active device emits PEMF signal; placebo/control device does not emit PEMF signal

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Orthofix Physio-Stim Model 3315OA

Active device emits PEMF signal; placebo/control device does not emit PEMF signal

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject must be able to wear the investigational device so that there is adequate PEMF exposure to the knee.
2. Subject must have a body mass index ≤ 45 at the time of consent.
3. Subject must be at least forty (≥ 40) years of age of age at the time of consent.
4. Subject must have an established diagnosis of primary femorotibial OA in the target knee by modified American College of Rheumatology criteria for at least 6 months and at least one of the following:

i. Stiffness less than 30 min ii. Crepitus (noise or cracking on knee motion)
5. Subject must have symptomatic Kellgren-Lawrence (K-L) Grades 1-3 OA by radiograph (PA flexion) within 90 days of screening, where the K-L grades are defined as:

Grade 1: doubtful narrowing of joint space and possible osteophytic lipping; Grade 2: definite osteophytes and definite narrowing of joint space; Grade 3: moderate multiple osteophytes and definite narrowing of joint space and some sclerosis and possible deformity of bone contour
6. Subject must have a visual analog pain score between 4 cm and 8 cm on a 10 cm scale in the target knee at the time of screening.
7. Subject must have a normal tibiofemoral angle (0-8°) and a joint space width of ≥ 3mm confirmed by radiograph.
8. Subject must be ambulatory.
9. Subject must NOT have had arthroscopy within 8 weeks of randomization.
10. Subject must NOT have had viscosupplementation within 8 weeks of randomization.
11. Subject must NOT have had NSAIDs within 1 week of randomization (low-dose aspirin as cardioprotective prophylaxis is permitted).
12. Subject must be willing to discontinue corticosteroids administered by any route except intranasal spray, steroid- containing ophthalmic solutions and anti-asthmatics.
13. Subject must be willing to take acetaminophen (up to 3000 mg/day) as pain medication for the duration of the study. Other pain medications may be allowed during the course of the study if the subject meets specific criteria.
14. Subject must be willing to STOP taking any pain medications 24 hours prior any scheduled study visit.
15. Subject must NOT have participated in a clinical study within the past 12 weeks that required the use of an investigational device, drug or biologic.
16. Subjects must be proficient in English.
17. Subject must be willing and able to sign an informed consent document.
18. Subjects must be willing and able to comply with all study procedures for the duration of the clinical study.

Exclusion Criteria

1. Subjects who have a body mass index \> 45 at the time of consent.
2. Subjects with a diagnosis of inflammatory arthritis (rheumatoid arthritis, gout, joint infection, Lyme disease, SLE, etc.).
3. Subjects with a diagnosis of secondary arthritis (acromegaly, Charcot's arthropathy, hemochromatosis, Wilson's disease, ochronosis, etc.).
4. Subjects with confounding factors such as ipsilateral hip OA or chronic pain syndromes (fibromyalgia, Crohn's disease, ulcerative colitis, interstitial cystitis).
5. Subjects who have had an injury or an acute traumatic injury to the index knee within 6 months of screening will be excluded.
6. Subjects who have had treatment of the target knee with intra-articular injections of steroids within 8 weeks of screening.
7. Subjects who have had intra-articular injections of hyaluronic acid within 8 weeks of screening.
8. Subjects who plan to have surgery on the target knee within the study period.
9. Subjects who have used electrotherapy or acupuncture for OA of the target knee within 4 weeks of screening.
10. Subjects with significant and clinically evident mal-alignment of the target knee (\> 10 degrees varus or valgus in the target knee).
11. Subjects with surgical metallic hardware in the target knee.
12. Subjects with pain in any other area of the lower extremities or back that is equal to or greater than the pain in the target knee.
13. Subjects who have contraindications to MRI and X-rays, for example, implanted electrical devices (cardiac pacemakers, deep brain stimulators).
14. Subjects with a current malignancy or who have received treatment for malignancy with the last 5 years, with the exception of resected basal cell carcinoma and squamous cell carcinoma of the skin.
15. Subjects who have an active substance abuse problem (drugs or alcohol) or a history of chronic substance abuse (\> 5 years).
16. Subjects with skin breakdown or infection in the area where the study device will be placed.
17. Subjects with any chronic conditions (e.g., diabetes, hypertension, congestive heart failure, etc.) that have not been well-controlled for at least 3 months prior to screening.
18. Subjects who have any ongoing litigation for worker's compensation.
19. Subjects with any condition, in the opinion of the Investigator that might interfere with the evaluation of the study objectives.
20. Subjects who are unwilling or unable to adhere to the follow up schedule and procedures.
21. Subjects who are pregnant.
22. Subjects who are prisoners.

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No